Precision Oncology

2 articles in this category

biotechnologyprecision oncologyhealthcare

Tango Therapeutics: Clinical Breakthrough in Pancreatic Cancer Signals Upside Potential

Tango Therapeutics reported exceptional results from its vopimetostat combination trial in pancreatic cancer, with a 92% objective response rate. This positions the company for a potential accelerated regulatory path. However, the stock trades near its 52-week high and RSI is overbought, creating short-term risk. The 21-day outlook is cautiously positive given the strong fundamental catalyst.

Jun 8, 2026TNGX

Stock Weather AIBiotechnologyPrecision Oncology

Erasca – 2026-01-13 - Increase Confidence 6/10

Negative free cash flow and high debt are offset by bullish technicals and a key conference catalyst, pointing to near-term upside.

Jan 13, 2026ERAS